Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.35 |
| ▸ | TET3 | O43151 | 1/20 | 0.35 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9514386 | 0.89 | TSHR (0.39) | TDP1GRNSORT1TET2TET3 | |
| SCHEMBL11986243 | 0.82 | TDP1 (0.59) | TDP1TSHRSMN1; SMN2TP53 | |
| SCHEMBL13254368 | 0.82 | TDP1 (0.40) | TDP1TSHRSMN1; SMN2TP53GRIK1 | |
| SCHEMBL7412371 | 0.80 | TDP1 (0.39) | TDP1GRNSORT1TET2TET3 | |
| SCHEMBL9911941 | 0.78 | ALDH1A1 (0.32) | GRNSORT1TSHRSMN1; SMN2 | |
| SCHEMBL11606875 | 0.77 | SLC1A3 (0.45) | TDP1GRNSORT1TET2TET3 | |
| SCHEMBL9911944 | 0.76 | ALDH1A1 (0.37) | TSHR | |
| SCHEMBL15847389 | 0.74 | PGD (0.30) | — | |
| SCHEMBL7415744 | 0.74 | TDP1 (0.40) | TDP1TET2TET3TET1GRIK1 | |
| SCHEMBL4144935 | 0.72 | GRN (0.36) | TDP1GRNSORT1TET2TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952061-B2 | Methods and compounds regulating the erythroid response to iron deficiency | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130072428-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120142590-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142590-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | MCL1, FECH, MPL | TDP1 4776/4885GRN 4181/4885SORT1 4788/4885 |
| US-20130072428-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | HIF1AN, IDH2, IDH3B | TDP1 4822/4885GRN 4074/4885SORT1 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.